Patents Assigned to Canbas Co., Ltd.
-
Patent number: 10149887Abstract: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells, and combinations of T cell activating agents and/or an immune checkpoint inhibitors with and without peptides and peptidimimetics. The invention compounds and combinations can be used to inhibit cell growth, such as treat a tumor or cancer.Type: GrantFiled: October 21, 2016Date of Patent: December 11, 2018Assignee: CanBas Co., Ltd.Inventor: Takumi Kawabe
-
Publication number: 20170112894Abstract: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells, and combinations of T cell activating agents and/or an immune checkpoint inhibitors with and without peptides and peptidomimetics. The invention compounds and combinations can be used to inhibit cell growth, such as treat a tumor or cancer.Type: ApplicationFiled: October 21, 2016Publication date: April 27, 2017Applicant: CanBas Co., Ltd.Inventor: Takumi KAWABE
-
Patent number: 9221872Abstract: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by inhibiting G2 cell cycle checkpoint. Thus, invention compounds can be used to inhibit cell growth alone or be used in combination with a nucleic acid damaging treatment to inhibit cell growth.Type: GrantFiled: June 24, 2014Date of Patent: December 29, 2015Assignee: CANBAS CO., LTD.Inventors: Takumi Kawabe, Naoki Mine, Naoya Saito, Keiichi Sakakibara, Takuji Sato
-
Patent number: 8415357Abstract: Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.Type: GrantFiled: November 19, 2010Date of Patent: April 9, 2013Assignee: Canbas Co., Ltd.Inventors: Takumi Kawabe, Machiyo Ishigaki, Takuji Sato, Sayaka Yamamoto, Yoko Hasegawa
-
Patent number: 8084454Abstract: Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.Type: GrantFiled: April 11, 2008Date of Patent: December 27, 2011Assignee: Canbas Co., Ltd.Inventors: Takumi Kawabe, Machiyo Ishigaki, Takuji Sato, Sayaka Yamamoto, Yoko Hasegawa
-
Publication number: 20110092514Abstract: Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.Type: ApplicationFiled: November 19, 2010Publication date: April 21, 2011Applicant: CanBas Co., Ltd.Inventors: TAKUMI KAWABE, Machiyo Ishigaki, Takuji Sato, Sayaka Yamamoto, Yoko Hasegawa
-
Patent number: 7851592Abstract: The invention provides compositions and methods for inhibiting Chk1 and/or Chk2 kinases. Also provided are compositions and methods for inhibiting G2 cell arrest checkpoint, particularly in mammalian, e.g., human, cells. The compositions and methods of the invention are also used to treat disorders of cell growth, such as cancer. In particular, the invention provides methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA damaging agents and treatments. Also provided are methods for screening for compounds able to interact with, e.g., inhibit, enzymes involved in the G2 cell cycle arrest checkpoint, such as Chk1 and/or Chk2/Cds1 kinase.Type: GrantFiled: October 15, 2004Date of Patent: December 14, 2010Assignee: CanBas Co. Ltd.Inventors: Masashi Suganuma, Takumi Kawabe
-
Patent number: 7652042Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.Type: GrantFiled: June 2, 2008Date of Patent: January 26, 2010Assignee: Canbas Co., Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Patent number: 7629364Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.Type: GrantFiled: June 2, 2008Date of Patent: December 8, 2009Assignee: Canbas Co., Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Publication number: 20080293137Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.Type: ApplicationFiled: June 2, 2008Publication date: November 27, 2008Applicant: CanBas Co., Ltd.Inventors: TAKUMI KAWABE, Hidetaka Kobayashi
-
Publication number: 20080275057Abstract: Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.Type: ApplicationFiled: April 11, 2008Publication date: November 6, 2008Applicant: CanBas Co., Ltd.Inventors: Takumi Kawabe, Machiyo Ishigaki, Takuji Sato, Sayaka Yamamoto, Yoko Hasegawa
-
Publication number: 20080227827Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.Type: ApplicationFiled: June 2, 2008Publication date: September 18, 2008Applicant: CanBas Co., Ltd.Inventors: Takumi KAWABE, Hidetaka KOBAYASHI
-
Patent number: 7407985Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.Type: GrantFiled: January 17, 2006Date of Patent: August 5, 2008Assignee: Canbas Co., Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Patent number: 7358046Abstract: The present disclosure provides methods for determining the sensitivity of cancerous cells to various anti-cancer therapies and predicting the efficacy of these therapies. Specifically, the present disclosure provides methods for predicting the efficacy of one or more candidate anti-cancer therapies in a patient, based on determining the sensitivity of the patient's cancerous cells after exposure to candidate anti-cancer therapies in vitro. The disclosure further provides methods for predicting the efficacy of candidate anti-cancer therapies by using an in vitro sensitivity test of the patient's cancerous cells and a surrogate in vivo efficacy test of the patient's cancerous cells grafted into a surrogate host. The disclosure further provides methods for selecting the most efficacious anti-cancer therapy(s) for a patient, thereby avoiding ineffective or unnecessary treatments.Type: GrantFiled: August 6, 2004Date of Patent: April 15, 2008Assignee: Canbas Co., Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Patent number: 7125842Abstract: The invention relates to compounds including peptides and peptidomimetics having anti-fungal activity alone, and in combination with other agents that have anti-fungal activity. The invention includes the use of cell cycle G2 checkpoint abrogators as anti-fungal agents, such as anti-fungal medicine.Type: GrantFiled: April 5, 2004Date of Patent: October 24, 2006Assignee: CanBas Co. Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Publication number: 20060122269Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.Type: ApplicationFiled: January 17, 2006Publication date: June 8, 2006Applicant: CanBas Co., Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Publication number: 20060084610Abstract: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by inhibiting G2 cell cycle checkpoint. Thus, invention compounds can be used to inhibit cell growth alone or be used in combination with a nucleic acid damaging treatment to inhibit cell growth.Type: ApplicationFiled: September 6, 2005Publication date: April 20, 2006Applicant: CanBas Co., Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Patent number: 7030111Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.Type: GrantFiled: June 6, 2003Date of Patent: April 18, 2006Assignee: Canbas Co., Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Patent number: 6995135Abstract: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by inhibiting G2 cell cycle checkpoint. Thus, invention compounds can be used to inhibit cell growth alone or be used in combination with a nucleic acid damaging treatment to inhibit cell growth.Type: GrantFiled: January 17, 2003Date of Patent: February 7, 2006Assignee: CanBas Co., Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Patent number: 6881575Abstract: The invention provides compositions and methods for inhibiting Chk1 and/or Chk2 kinases. Also provided are compositions and methods for inhibiting G2 cell arrest checkpoint, particularly in mammalian, e.g. human cells. The compositions and methods of the invention are also used to treat disorders of cell growth, such as cancer. In particular, the invention provides methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA damaging agents and treatments. Also provided are methods for screening for compounds able to interact with, e.g., inhibit, enzymes involved in the G2 cell cycle arrest checkpoint, such as Chk1 and/or Chk2/Cds1 kinase.Type: GrantFiled: September 21, 2000Date of Patent: April 19, 2005Assignee: Canbas Co., Ltd.Inventors: Masashi Suganuma, Takumi Kawabe